|
Biocon Biologics, a fully integrated global biosimilars company and subsidiary of Biocon will present at the 43rd Annual J P Morgan Healthcare Conference on Thursday, January 16, 2025 in San Francisco, California.
Shreehas Tambe, chief executive officer and managing director, will present on behalf of the company in a session, as part of the APAC Conference Track.
The presentation will focus on enabling equitable access to healthcare and treatment options including highlighting the company’s growing range of products and pipeline, and a global presence in over 120 emerging and advanced markets that’s currently serving over 5 million patients worldwide.
The Bengaluru-based company’s R&D leadership has led it to be first to market for many of its biosimilars, with 10 approved products and several more on the horizon. Its pipeline is strategically aligned to the top global therapeutic areas including oncology, immunology, diabetes, bone health, and ophthalmology, which helps creating an opportunity to answer unmet needs across a range of opportunities.
Shreehas Tambe, CEO & managing director, Biocon Biologics Ltd, said: “This year’s J P Morgan Healthcare Conference marks an exciting milestone for Biocon Biologics as we celebrate the first anniversary of integrating the acquired global biosimilars business and engage with investors, analysts, and healthcare leaders to showcase our rapidly growing biosimilars portfolio. Looking ahead, we are poised for a transformative year, marked by a series of key product launches, strategic market expansions, and further innovation in our robust pipeline."
|